Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Company Overview

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Key Stats

• Today's Range: $37.94 to $41.00
• 50-Day Range: $23.12 to $39.04
• 52-Week Range: $8.13 to $41.00
• Volume: 28,118 shs
• Average Volume: 36,202 shs
• Market Capitalization: $364.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $64.25
• Consensus Rating: Buy

Tvardi Therapeutics Stock Analysis - MarketRank™

Tvardi Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 397th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Tvardi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Tvardi Therapeutics has a consensus price target of $64.25, representing about 63.9% upside from its current price of $39.20.

Amount of Analyst Coverage

Tvardi Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.96% of the float of Tvardi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tvardi Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Tvardi Therapeutics has recently decreased by 0.76%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tvardi Therapeutics does not currently pay a dividend.

Dividend Growth

Tvardi Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.96% of the float of Tvardi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tvardi Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Tvardi Therapeutics has recently decreased by 0.76%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Tvardi Therapeutics this week, compared to 1 article on an average week.

Search Interest

9 people have searched for TVRD on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.

MarketBeat Follows

2 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Tvardi Therapeutics is held by insiders.

Percentage Held by Institutions

44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TVRD Stock Analysis - Frequently Asked Questions

How have TVRD shares performed this year?

Tvardi Therapeutics' stock was trading at $29.09 on January 1st, 2025. Since then, TVRD stock has increased by 34.8% and is now trading at $39.20.

How were Tvardi Therapeutics' earnings last quarter?

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.49. Tvardi Therapeutics had a negative trailing twelve-month return on equity of 565.83% and a negative net margin of 678.79%.

How do I buy shares of Tvardi Therapeutics?

Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVRD
• Previous Symbol: NASDAQ:TVRD
• CIK: 1346830
• Web: N/A
• Phone: (203) 406-3700
• Fax: 203-567-1510
• Employees: 80
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Tvardi Therapeutics: $64.25
• High Price Target: $78.00
• Low Price Target: $52.00
• Potential Upside/Downside: +71.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.87 million
• Net Margins: -678.79%
• Pretax Margin: -453.48%
• Return on Equity: -565.83%
• Return on Assets: -66.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.04
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 49.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.02) per share
• Price / Book: -12.37

Miscellaneous

• Outstanding Shares: 9,380,000
• Free Float: 9,086,000
• Market Cap: $350.53 million
• Optionable: N/A
• Beta: 0.24